









市場行情
/
股票
/
nasdaq-rapt
/

RAPT Therapeutics Inc

RAPT

35.420USD

-0.420-1.17%

收盤 12/26, 16:00（美東）報價延遲15分鐘

597.02M總市值

虧損本益比TTM



RAPT Therapeutics Inc

35.420

-0.420-1.17%

概覽公司財務分析

概覽

公司

財務

分析

關於 RAPT Therapeutics Inc 公司

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

RAPT Therapeutics Inc簡介



公司代碼RAPT

公司名稱RAPT Therapeutics Inc

上市日期Oct 31, 2019

CEOWong (Brian)

員工數量68

證券類型Ordinary Share

年結日Oct 31

公司地址561 Eccles Ave

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94080

電話16504899000

網址https://rapt.com/

公司代碼RAPT

上市日期Oct 31, 2019

CEOWong (Brian)

RAPT Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Scott N. Braunstein, M.D.

Independent Director

Dr. Ashley Dombkowski, Ph.D.

Independent Director

Dr. Michael F. Giordano, M.D.

Independent Director

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

Dr. Mary Ann Gray, Ph.D.

Independent Director

Ms. Lori Lyons-Williams

Independent Chairman of the Board

Dr. Brian Wong, M.D., Ph.D.

President, Chief Executive Officer, Director

Dr. Dirk Brockstedt, Ph.D.

Chief Scientific Officer

Mr. Rodney K. B. Young

Chief Financial Officer

Ms. Linda Kozick

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Scott N. Braunstein, M.D.

Independent Director

Dr. Ashley Dombkowski, Ph.D.

Independent Director

Dr. Michael F. Giordano, M.D.

Independent Director

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

Dr. Mary Ann Gray, Ph.D.

Independent Director

Ms. Lori Lyons-Williams

Independent Chairman of the Board

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Medicxi Ventures (UK) LLP

10.08%

Forbion Capital Partners

6.62%

TCG Crossover Management, LLC

5.90%

Foresite Capital Management, LLC

5.64%

RTW Investments L.P.

5.31%

其他

66.45%

持股股東

佔比

Medicxi Ventures (UK) LLP

10.08%

Forbion Capital Partners

6.62%

TCG Crossover Management, LLC

5.90%

Foresite Capital Management, LLC

5.64%

RTW Investments L.P.

5.31%

其他

66.45%

股東類型

持股股東

佔比

Venture Capital

17.34%

Investment Advisor

15.93%

Hedge Fund

12.00%

Private Equity

10.22%

Investment Advisor/Hedge Fund

9.52%

Research Firm

0.32%

Individual Investor

0.25%

Sovereign Wealth Fund

0.05%

其他

34.36%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

290

16.78M

61.62%

-1.23M

2025Q2

295

16.40M

99.19%

-1.13M

2025Q1

309

29.14M

109.47%

+11.54M

2024Q4

309

140.52M

106.54%

+100.36M

2024Q3

304

31.22M

87.82%

-13.95M

2024Q2

305

33.18M

93.85%

-9.52M

2024Q1

295

33.76M

95.60%

-5.47M

2023Q4

282

36.46M

106.02%

-3.53M

2023Q3

281

36.40M

105.98%

-3.26M

2023Q2

295

35.63M

103.77%

-4.21M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Medicxi Ventures (UK) LLP

2.79M

16.89%

Jun 30, 2025

Forbion Capital Partners

440.18K

2.66%

+440.18K

Jun 30, 2025

TCG Crossover Management, LLC

1.64M

9.89%

Jun 30, 2025

Foresite Capital Management, LLC

1.56M

9.45%

Jun 30, 2025

RTW Investments L.P.

1.47M

8.89%

-1.00

-0.00%

Jun 30, 2025

OrbiMed Advisors, LLC

1.64M

9.93%

-2.00

-0.00%

Jun 30, 2025

Deep Track Capital LP

751.42K

4.54%

-1.00

-0.00%

Jun 30, 2025

The Vanguard Group, Inc.

880.05K

5.32%

-154.80K

-14.96%

Jun 30, 2025

Nantahala Capital Management, LLC

951.61K

5.75%

+325.00K

+51.87%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Invesco Dorsey Wright SmallCap Momentum ETF

0.56%

Avantis US Small Cap Equity ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Schwab U.S. Broad Market ETF

Blueprint Chesapeake Multi-Asset Trend ETF

Virtus LifeSci Biotech Clinical Trials ETF

DFA Dimensional US Core Equity Market ETF

iShares Russell 3000 ETF

Pacer WealthShield ETF

T Rowe Price Small-Mid Cap ETF

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.56%

Avantis US Small Cap Equity ETF

佔比0.02%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.01%

Schwab U.S. Broad Market ETF

佔比0%

Blueprint Chesapeake Multi-Asset Trend ETF

佔比0%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0%

DFA Dimensional US Core Equity Market ETF

佔比0%

iShares Russell 3000 ETF

佔比0%

Pacer WealthShield ETF

佔比0%

T Rowe Price Small-Mid Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jun 13, 2025

Merger

8→1

公告日期

類型

比率

Jun 13, 2025

Merger

8→1

常見問題

RAPT Therapeutics Inc的前五大股東是誰？



RAPT Therapeutics Inc的前五大股東如下：
Medicxi Ventures (UK) LLP
持有股份：2.79M
佔總股份比例：16.89%。
Forbion Capital Partners
持有股份：440.18K
佔總股份比例：2.66%。
TCG Crossover Management, LLC
持有股份：1.64M
佔總股份比例：9.89%。
Foresite Capital Management, LLC
持有股份：1.56M
佔總股份比例：9.45%。
RTW Investments L.P.
持有股份：1.47M
佔總股份比例：8.89%。